4.6 Article

Identification of the Putative Binding Site of a Benzimidazole Opioid (Etazene) and Its Metabolites at μ-Opioid Receptor: A Human Liver Microsomal Assay and Systematic Computational Study

期刊

MOLECULES
卷 28, 期 4, 页码 -

出版社

MDPI
DOI: 10.3390/molecules28041601

关键词

synthetic opioids; etazene; docking; molecular dynamics; mu-opioid receptor; liver microsomal assay

向作者/读者索取更多资源

The synthetic benzimidazole opioid etazene, a recreational drug, has gained popularity as a novel psychoactive substance on the illegal/darknet market. This study investigated the metabolism of etazene and its binding mechanism at the mu-opioid receptor (MOR). The results suggest that etazene and its metabolites may act as strong MOR agonists, highlighting the necessity of experimental validation and providing insights for predicting potential analogs and regulating illicit substances.
The synthetic benzimidazole opioid etazene (which has a 70-times higher analgesic activity than morphine), a recreational drug, has gained popularity as a novel psychoactive substance (NPS) on the illegal/darknet market; however, no experimental information is available at the molecular level on the binding mechanism and putative binding site of etazene and its metabolites at the mu-opioid receptor (MOR). In the present study, we investigated the metabolism of etazene in human liver microsomes using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). We also explored the possibilities of MOR activation by etazene and its metabolites by studying their binding mechanisms and interaction profiles at an active-state MOR model via molecular docking, binding free energy calculations, and all-atom molecular dynamics (MD) simulations. The putative metabolites of etazene were also predicted using the ADMET Predictor 10.1. The molecular docking studies and free energy calculations showed that etazene and its metabolites (M1, M2, and M5-M7) exhibited strong predicted binding affinity at MOR and showed overlapped binding orientation with MOR-bound agonist BU72, which was co-crystallized in the MOR X-ray crystal structure (PDB ID: 5C1M). MD also confirmed the stability of the MOR-etazene and MOR-M6 complexes. These results suggest that etazene and its metabolites may act as strong MOR agonists, highlighting the necessity of experimental validation. The insights from this study, such as key interactions between etazene and its metabolites and the MOR, will allow authorities to predict potential analogs and clarify the target-protein interactions associated with this illicit substance, granting advanced or rapid reactions to confiscating or banning potential emerging drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据